Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$379M |
| 2 |
Starbucks
SBUX
|
+$371M |
| 3 |
APC
Anadarko Petroleum
APC
|
+$287M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$263M |
| 5 |
Tesla
TSLA
|
+$253M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.27B |
| 2 |
ANDV
Andeavor
ANDV
|
+$1.11B |
| 3 |
AET
Aetna Inc
AET
|
+$535M |
| 4 |
Microsoft
MSFT
|
+$350M |
| 5 |
Amazon
AMZN
|
+$290M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.69% |
| 2 | Technology | 13.64% |
| 3 | Financials | 12.49% |
| 4 | Consumer Discretionary | 10.83% |
| 5 | Industrials | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OPRA
3451
Opera Ltd
OPRA
$1.69B
| $146K | ﹤0.01% |
26,241
-145,191
| -85% | -$990K |
|
3452
PUT
Prospect Capital
PSEC
$1.16B
| $146K | ﹤0.01% |
+23,200
| New | +$157K |
|
|
NEOS
3453
DELISTED
Neos Therapeutics, Inc
NEOS
| $146K | ﹤0.01% |
88,643
+17,927
| +25% | +$50.3K |
|
3454
Aquestive Therapeutics
AQST
$602M
| $145K | ﹤0.01% |
+23,010
| New | +$290K |
|
3455
Rafael Holdings
RFL
$114M
| $145K | ﹤0.01% |
18,529
-26,205
| -59% | -$218K |
|
3456
WillScot Mobile Mini Holdings
WSC
$4.08B
| $144K | ﹤0.01% |
15,338
-244,395
| -94% | -$3.46M |
|
|
BGG
3457
DELISTED
Briggs & Stratton Corp.
BGG
| $144K | ﹤0.01% |
11,019
-46,110
| -81% | -$711K |
|
|
AHRT
3458
AH Realty Trust
AHRT
$502M
| $143K | ﹤0.01% |
10,185
-48,289
| -83% | -$720K |
|
|
BFK
3459
DELISTED
BlackRock Municipal Income Trust
BFK
| $143K | ﹤0.01% |
+11,750
| New | +$145K |
|
3460
BlackRock MuniAssets Fund
MUA
$667M
| $143K | ﹤0.01% |
+11,147
| New | +$143K |
|
|
CHAP
3461
DELISTED
Chaparral Energy, Inc.
CHAP
| $143K | ﹤0.01% |
28,982
-184,589
| -86% | -$2.35M |
|
|
AVK
3462
Advent Convertible and Income Fund
AVK
$553M
| $142K | ﹤0.01% |
+11,651
| New | +$158K |
|
3463
B2Gold
BTG
$7.56B
| $142K | ﹤0.01% |
48,689
-231,460
| -83% | -$602K |
|
3464
Marchex
MCHX
$78M
| $142K | ﹤0.01% |
53,729
-68,146
| -56% | -$192K |
|
|
ITCI
3465
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $142K | ﹤0.01% |
+12,500
| New | +$202K |
|
3466
Galmed Pharmaceuticals
GLMD
$4.22M
| $141K | ﹤0.01% |
14
-215
| -94% | -$3M |
|
|
ORBC
3467
DELISTED
ORBCOMM, Inc.
ORBC
| $141K | ﹤0.01% |
17,062
-503,787
| -97% | -$4.7M |
|
3468
Inovio Pharmaceuticals
INO
$129M
| $140K | ﹤0.01% |
2,914
-2,556
| -47% | -$155K |
|
|
SVM
3469
Silvercorp Metals
SVM
$2.8B
| $139K | ﹤0.01% |
66,246
+41,354
| +166% | +$88.7K |
|
|
ETTX
3470
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $139K | ﹤0.01% |
34,143
-45,294
| -57% | -$298K |
|
|
FTD
3471
DELISTED
FTD Companies, Inc. Common Stock
FTD
| $139K | ﹤0.01% |
94,165
-184,066
| -66% | -$392K |
|
3472
BlackRock Credit Allocation Income Trust
BTZ
$942M
| $138K | ﹤0.01% |
12,340
-5,906
| -32% | -$69.1K |
|
3473
Microvision
MVIS
$52M
| $138K | ﹤0.01% |
15,195
-13,759
| -48% | -$194K |
|
3474
ImmunityBio
IBRX
$8.03B
| $137K | ﹤0.01% |
118,066
-7,375
| -6% | -$16.9K |
|
3475
Ribbon Communications
RBBN
$365M
| $137K | ﹤0.01% |
28,463
-60,922
| -68% | -$353K |
|
Similar funds
Israel Englander's Q4 2018 Portfolio in Review
As of Q4 2018, Israel Englander held 4,541 positions worth $64.1B, down 21% from $81.6B the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.
Israel Englander withdrew a net $4.25B in Q4 2018, closing 844 positions and reducing 1,571 holdings. Its most notable exit was Andeavor, an estimated $1.11B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
Against the trend, Israel Englander opened a new position in Athenahealth, Inc. worth $135M.
- Israel Englander's largest Q4 2018 buy was Athenahealth, Inc.: 1,022,505 shares worth $135M.
- Israel Englander added most to Celgene Corp in Q4 2018, an estimated $379M increase.
- Israel Englander's biggest Q4 2018 reduction was Fortive, cutting an estimated $1.27B.
- Israel Englander fully exited Andeavor in Q4 2018, selling an estimated $1.11B.
- Israel Englander's ten largest holdings make up 6.7% of its $64.1B portfolio in Q4 2018.
- Israel Englander opened 702 new positions and closed 844 in Q4 2018.
- Israel Englander's portfolio value fell 21% quarter-over-quarter to $64.1B.
Based on Millennium Management's 13F filing for Q4 2018, filed 14 Feb 2019.